Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | IL1RN | P18510 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31644261 | 0.79 | CHRM2 (0.36) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL31316676 | 0.79 | CHRM2 (0.36) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL3847929 | 0.70 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL31300318 | 0.70 | MAP3K14 (0.45) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL31316665 | 0.70 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1A | |
| Hydrochloric Acid SCHEMBL31316673 | 0.69 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL20763587 | 0.68 | IL1RN (0.50) | IL1RNERAP2ERAP1 | |
| SCHEMBL23976501 | 0.68 | KDM1A (0.45) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL30216698 | 0.68 | CNR1 (0.36) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL22076748 | 0.67 | HTR2A (0.34) | ADRA2AADRA2BADRA2CADRA1AIL1RN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4624473-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |